Photocure ASA Reports Strong Q2 2025 Performance
OSLO, Norway, July 30, 2025 — Photocure ASA, a leading specialty pharmaceutical company, has announced its financial results for the second quarter of 2025, showcasing robust growth and strategic advancements. The company, listed on Oslo Bors ASA, reported Hexvix®/Cysview® revenues of NOK 135.6 million, marking a significant increase from NOK 122.4 million in the same quarter of the previous year. This achievement underscores Photocure’s commitment to innovation and excellence in the healthcare sector.
Despite a decrease in EBITDA to NOK 14.8 million from NOK 27.8 million in Q2 2024, which included a milestone payment of NOK 21.6 million, Photocure remains optimistic about its financial trajectory. The company anticipates product revenue growth between 7% and 11% and expects a year-over-year improvement in EBITDA for 2025. While specific EBITDA guidance is not provided, Photocure is confident in the continued operating leverage flow-through in its core commercial business and anticipates significant growth in milestone achievements.
Photocure ASA, founded in 1997 and headquartered in Oslo, Norway, is renowned for its innovative pharmaceutical products and technical medical equipment. The company’s flagship products, Hexvix®/Cysview®, are pivotal in the detection and management of bladder cancer. Additionally, Photocure is advancing its pipeline with Visonac, aimed at treating moderate to severe acne, and Cevira, targeting human papilloma virus infection and precancerous lesions of the cervix.
The company’s strategic focus on expanding its product offerings and enhancing its market presence is evident in its recent performance. Photocure’s ability to deliver all-time high Hexvix/Cysview revenues and maintain a streak of nine consecutive quarters of positive EBITDA highlights its resilience and strategic acumen.
As Photocure continues to navigate the competitive landscape of the pharmaceutical industry, its commitment to research, development, and strategic partnerships positions it well for sustained growth. Investors and stakeholders can find more information about the company and its products on their website at www.photocure.com .
With a market capitalization of NOK 1.68 billion and a price-to-earnings ratio of 873.55, Photocure ASA remains a significant player in the healthcare sector, dedicated to improving patient outcomes through innovative solutions.